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The development of monoclonal antisera by the hybridoma technique permits the 
expansion of knowledge about  human  lymphoma.  We report a  remarkable lineage 
among  the  large  cell  lymphomas  that  is  devoid  of Ia-like antigen,  exhibits  clonal 
surface  (or cytoplasmic) IgG, and  reacts with  monoclonal antisera  previously dem- 
onstrated to react only with early thymocytes (1). The present findings: (a) extend our 
knowledge of the specificity of a  group of monoclonal antisera widely employed and 
(b) provide an additional discriminant for the subdivision of human lymphoma. If, as 
some  have  proposed  (2),  lymphomas  represent  expansions  of specific  lymphocyte 
subsets, this phenotype may represent a significant stage in lymphocyte development. 
Materials  and  Methods 
Conventional Lymphocyte Surface Markers.  The three cases that were the subject of this investi- 
gation were all designated by the Pathology Department  (Massachusetts General  Hospital, 
Boston, Mass.) as non-Hodgkin's lymphomas of the large cell or histiocytic type: the first and 
third were of diffuse histology; the second was nodular. Cell suspensions of lymphoma tissue 
were prepared in medium 199 (Microbiological Associates, Walkersville, Md.) by sieving tissue, 
obtained fresh from the operating room, through a stainless steel mesh. All surface membrane 
studies were performed on the day of biopsy after viability had been assessed by trypan blue 
dye exclusion. 
Cell surface immunoglobulin (SIg) was determined with fluorescein-conjugated goat antise- 
rums specific for the IgG, IgM, and IgD heavy chains of human immunoglobulin and for the 
kappa and lambda light chains (Meloy Laboratories, Inc., Springfield, Va.). Lymphoid cells 
(10  in 0.05 ml of medium 199) were incubated with 0.05 ml of undiluted fluorescein-conjugated 
antiserums for 1 h at 37°C, washed three times at room temperature with phosphate-buffered 
saline (pH  7.4),  and suspended in phosphate-buffered glycerine. The cells were placed on a 
slide, overlayed with a cover slip, and examined with a Zeiss ultraviolet microscope equipped 
with an Osram HBD 200 mercury arc lamp and a fluorescein isothiocyanate-495 nm interfer- 
ence  primary  filter.  A  minimum  of  200  lymphocytes  were  examined;  thereafter,  a  10% 
transmitting filter was interposed in the optical system; 200 cells were again examined. Bright 
cells were  defined as those  visible with  the  reduced  light. The  technical details have been 
described in earlier publications (3-5). Cytoplasmic immunoglobulin  (CIg)  was determined 
with 1:10 dilutions of the same fluorescein-conjugated antiserums and air-dried methanol-fixed 
lymphocyte preparations. 
Cell suspensions that formed spontaneous rosettes with sheep erythrocytes were assessed by 
adding lymphoid cells (0.5  ×  106 in 0.4 ml of medium  199  that  contained 0.1%  gelatin)  to 
sheep  erythrocytes (0.4  ml  of an  0.5%  suspension  in  medium  199  of washed  pooled sheep 
erythrocytes obtained from BBL Microbiology Systems, Becton, Dickinson & Co., Cockeysville, 
Md.) in the presence of 9% absorbed and inactivated AB serum. The mixture was incubated 
for 10 rain at 37°C, centrifuged at room temperature for 5 rain at  150 g, and incubated for at 
least 2 h at 4°C (6). Receptor for the Fc portion of the immunoglobulin molecule was assayed 
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with sheep erythrocytes coated with IgG (IgGEA rosettes)  (7). The IgG fraction of rabbit anti- 
sheep cell stroma was obtained from N. L. Cappel Laboratories, Cochranville, Pa. Complement 
receptor was detected with sheep erythrocytes sensitized by the addition of hemolysin ambo- 
ceptor and mouse complement by the method of Pincus et al.  (8). 
Thymus-related  surface  antigens  were  evaluated  with  the  globulin  fraction  of a  rabbit 
antiserum to human fetal thymus absorbed with A-positive erythrocytes and chronic lympho- 
cytic  leukemia  cells,  as  described  previously  (9). The  nonfluorescent  anti-thymus  globulin 
reacted  with  lymphoma cells  that  were  then  washed  and  reincubated  with  a  fluorescein- 
conjugated goat anti-rabbit globulin antiserum  (Meloy Laboratories, Inc.). The percentage of 
lymphoma cells that fixed the rabbit globulin was determined with the fluorescence microscope. 
Terminal deoxynucleotidyl transferase (TdT) was also determined by an indirect immunoflu- 
orescence assay; the reagents employed were obtained from the Bethesda Research Laboratories, 
Rockville, Md. (10). 
Surface Marker Analysis with Hybridoma Antisera.  Nonfluoresceinated monoclonal mouse hy- 
bridoma antisera were kindly supplied by P. C. Kung and G. Goldstein of  Ortho Pharmaceutical 
Corp.,  Raritan,  N. J.  as  lyophilized  ascites  proteins.  These  antisera  have  been  extensively 
studied in other laboratories (1, 11-14). 1 X 106 lymphocytes were incubated with 50 #1 (10 #g/ 
ml)  of each of the following mouse hybridoma antiserums:  OKT1  (all  T  cells  [11]), OKT3 
(peripheral T  cells  [1]), OKT4 (inducer/helper T  cells [12]), OKT5 and OKT8 (suppressor/ 
cytotoxic T  cells [1]), OKT6 (common thymocytes [1]), OKT9 (early thymocytes [1]), OKTI0 
(early thymocytes [1]), OKMI  (monocytes [13]), and OKI1  (Ia antigen [14]). After a 30-min 
incubation at 37°C, the lymphoma cells were washed twice with phosphate-buffered saline and 
reincubated  for 60 rain at  the same temperature  with  50 #1 of a  1:5 dilution of fluorescein- 
conjugated  goat anti-mouse  gamma globulin  (F[ab']2 fraction obtained  from N.  L.  Cappel 
Laboratories, Inc.). The cells were again washed twice and then examined under the fluorescence 
microscope as described above for surface immunoglobulin. 
Results 
The results  from three cases of large cell  (histiocytic)  lymphorna are presented  in 
Table I  and Fig.  1. With conventional surface marker techniques,  the first  two were 
identified  as  clonal  proliferations  of lymphocytes  that  bore  brightly  staining  IgG 
heavy chain and lambda light chain on their surface. The third specimen was devoid 
of surface immunoglobulin, but the lambda light-chain was detected in the cytoplasm 
of the fixed lymphoma smear, and a monoclonal immunoglobulin  (3,2.50 rag/100 mi) 
of IgG  heavy  chain  and  lambda  light  chain  was  demonstrated  in  the  serum  by 
immunoelectrophoresis  and agarose gel electrophoresis.  In all  three neoplasms, only 
a  minor population of cells reacted with the conventional T  cell reagents, i.e., rabbit 
anti-thymus antiserum and sheep erythrocytes. 
The  findings  with  the  monoclonal  antisera  were  unexpected  and  constitute  the 
basis  of this  report.  The  great  majority  of lymphoma  cells  from  all  three  tumors 
reacted  with  OKT9  and  OKT10,  considered  from  earlier  studies  to  detect  early 
thymocyte antigens (1), whereas very few cells reacted with the monoclonal antibody 
with  Ia  specificity  (OKll).  (The  reactivity  of OKI1  has  been  confirmed  in  our 
laboratory  by positive studies  [48-80% of cells staining brightly[  in  four out of four 
cases  of common  acute  lymphocytic  leukemia,  two  out  of  two  cases  of chronic 
lymphocytic leukemia,  and  three  other  large  cell  lymphomas  of B  lineage.)  A  low 
level of positivity with the monoclonals that identify mature T  cells  (OKT 1, OKT3, 
OKT4, OKT5, and OKT8) w~as consistent with our findings with conventional T  cell 
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FIG.  1.  Staining ofcase 3 with fluorescein-conjugated antiserums. (A) surface staining with Ortho 
monoclonal OKT9,  (B) surface staining with Ortho monoclonal OKT10,  (C) cytoplasmic staining 
with goat anti-kappa light-chain antiserum, (D) cytoplasmic staining with goat anti-lamhda light- 
chain antiserum. See Materials and Methods for details. Initial magnification ×  380. 
Discussion 
Three human  malignant  lymphomas have been identified with  monoclonal IgG 
either on the surface membrane or within the cytoplasm. These neoplasms react with 
the Ortho monoclonal antisera of hybridoma derivation OKT9 and OKT10, hereto- 
fore employed to identify early thymocytes (1), and fail to react with a  monoclonal 
antiserum  that  identifies the  Ia  antigen.  One  might  suggest  that  these  malignant 
lymphocytes possess both B and T  cell markers, an unusual finding in man, but one 
that has been described in the mouse (2, 15). Although this possibility is not excluded, 
it appears more likely that OKT9 and OKT10 are not specific for the T  lineage and 
react with an antigen present on some B cells. Thus, the specificity of the OKT9 and 
OKT10 antigens could be considered analogous to the Ia antigen first observed widely 
on B lymphocytes (16-18), and only more recently shown to be regularly present on 
activated T  cells (14, 19). 
The absence of the Ia  antigen  on  three lymphoid tumors  purported  to  be of B 
lineage also requires comment. It was  not surprising  to find the third neoplasm in 
Table I devoid of Ia because, despite its lymphoid morphology, this tumor was clearly 
differentiated along the plasma cell pathway with the loss of SIg and the presence of 
immunoglobulin in the cytoplasm: plasma cells lack the Ia antigen  (17,  20). At the 
present  time it seems plausible that the first two tumors  (Table I), which still have 
SIg, are also proceeding along the plasma cell differentiation pathway and have lost 
the Ia antigen as a consequence. 
The present  findings raise other considerations that  will  require investigation of 
additional  human  lymphomas  for  resolution.  First,  is  the  reciprocal  relationship 
between the Ia antigen and the antigens responsible for OKT9 and OKT 10 reactivity 
fortuitous, or does it have biological meaning in lymphocyte differentiation? Second, 
will the observation that  all three tumors bear IgG, an immunoglobulin found less 
frequently than IgM on the surface of non-Hodgkin's lymphoma cells (21), be born 
out  by subsequent  observations?  (Indeed,  the  three lymphomas  are  all  of iambda 1130  A. C.  AISENBERG AND B.  M.  WILKES  BRIEF  DEFINITIVE REPORT 
light-chain type, whereas kappa is the common light chain on the surface of lymphoid 
tumor cells as it is in normal circulating human immunoglobulin [21].) 
Finally, how frequently will this subset be observed in hyman lymphoma? Approx- 
imately 50-60% of the large cell or histiocytic lymphomas have been identified as B 
cell neoplasms on the basis of clonal surface immunoglobulin (2 l, 22), but there is no 
reason to suggest that the major fraction of these is of the phenotype described here 
(SIgG+ or CIgG+, OKT9+, OKT10+, Ia-). Indeed, the available evidence suggests 
that  most large cell lymphomas are Ia-positive (22).  Nonetheless,  the recognition of 
three such tumors in a period of a few months suggests that they are not uncommon. 
Further investigation  is needed  to establish the frequency of this phenotype and  its 
significance in lymphocyte differentiation. 
Summary 
The phenotype of three large cell (histiocytic) lymphomas of man has been defined 
with  conventional  lymphocyte  surface  marker  techniques,  a  panel  of monoclonal 
antisera of hybridoma derivation (Ortho Pharmaceutical Corp.), and the fluorescence 
microscope. Two tumors exhibited surface IgG of lambda light-chain type, whereas 
the  third  was  negative  for surface Ig but  contained  the same Ig in  the cytoplasm. 
With  the  monoclonal  antisera,  all  three  were  found  to  bear  two  surface  antigens 
(OKT9 and OKT10)  previously described on early thymocytes, and were devoid of 
the Ia antigen. The available knowledge suggests that these neoplasms represent the 
expansion of a  clone of B lymphocytes along the pathway that leads to plasma cell 
differentiation rather than a clone with both B and T  surface membrane markers. 
Received for publication  27June  1980. 
References 
1.  Reinherz,  E.  L.,  P.  C.  Kung,  G.  Goldstein,  R.  H.  Levey, and  S.  F.  Schlossman.  1980. 
Discrete  stages of human intrathymic differentiation: analysis  of normal thymocytes and 
leukemic lymphoblasts ofT-cell lineage. Proc. NatL Acad.  Sci.  U. S. A. 77:1588. 
2.  McKenzie, I. F. C., and T. Potter. 1979. Murine lymphocyte surface antigens.  Adv.  ImmunoL 
27:179. 
3.  Aisenberg,  A. C., and  K. J. Bloch.  1972. Immunoglobulins on the surface of neoplastic 
lymphocytes. N. EngL J. Med.  287:272. 
4.  Aisenberg,  A. C., and J. C. Long.  1975. Lymphocyte surface characteristics in malignant 
lymphoma. Am. at. Med.  58:300. 
5.  Aisenberg,  A. C., and B. Wilkes.  1976. Lymphosarcoma cell leukemia: the contribution of 
cell surface study to diagnosis.  Blood. 48:707. 
6.  Aisenberg,  A. C., J. C. Long, and B. Wilkes.  1974. Chronic lymphocytic leukemia cells: 
rosette formation and adherence to nylon fiber columns..]. NatL  Cancer Inst.  52:13. 
7. Jaffe, E. S., E. M. Shevach, M. M. Frank, and I. Green. 1974. Leukemia reticuloendothe- 
liosis. Presence of a receptor for cytophylic antibody. Am. J. Med.  57:108. 
8.  Pincus,  S.,  C.  Bianco,  and V.  Nussenzweig.  1972. Increased proportion of complement 
receptor lymphocytes in the peripheral blood of patients with chronic lymphocytic leuke- 
mia. Blood. 3:303. 
9.  Aisenberg,  A. C., K. J. Bloch, J. C. Long, and R. B. Colvin.  1973. Reaction of normal and 
chronic lymphocytic leukemia cells with an anti-thymocyte antiserum. Blood. 41:417. 
10.  Stass,  S.  A.,  H.  R.  Schumacher,  T.  P.  Kenekiis,  and  F.  J.  Bollum.  1979. Terminal A. C.  AISENBERG  AND B.  M.  WILKES  BRIEF DEFINITIVE REPORT  1131 
deoxynucleotidyl transferase immunofluorescence of bone marrow. Am. J.  Clin. Pathol. 72: 
898. 
ll.  Reinherz, E.  L.,  P. C.  Kung,  G. Goldstein, and  S.  F.  Schiossman.  1979. A  monocIonal 
antibody with  selective reactivity with  functionally mature  human  thymocytes and  all 
peripheral human T  cells.]. Irnmunol. 123:1312. 
19.  Reinherz,  E.  L.,  P. C.  Kung,  G. Goldstein, and  S.  F.  Schlossman.  1979. Separation of 
functional subsets of human T  cells by a monoclonal antibody. Proc. Natl.  Acad. Sd.  U. S. 
A. 76:4061. 
13.  Breard, J.,  E.  L.  Reinherz,  P.  C.  Kung,  G.  Goldstein, and  S.  F.  Schlossman.  1980. A 
monoclonal antibody reactive with human  peripheral blood monocytes. J.  Immunol.  124: 
1943. 
14.  Reinherz, E. L., P. C. Kung, J. M. Pesando, J. Ritz, G. Goldstein, and S. F. Schlossman. 
1979. Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation 
stimuli required for expression.J. Exp.  Med. 150:1472. 
15.  Greenberg,  R.  S.,  B.  J.  Mathieson,  P.  S.  Campbell, and  M.  M.  Zatz.  1977. Multiple 
occurrence of spontaneous AKR/J lymphomas with B and T cell characteristics.ft. ImmunoL 
118:1181. 
16.  Winchester, R. J., S. M.  Fu, P. Wernet, H. G. Kunket, B. Dupont, and C. Jersild.  1975. 
Recognition by pregnancy serums of non-HL-A alloantigens selectively expressed on  B 
lymphocytes.J. Exp.  Med. 141:924. 
17.  Schlossman, S. F., L. Chess, R. E. Humphreys, andJ. L. Strominger. 1976. Distribution of 
Ia-like molecules on the surface of normal and leukemic human cells. Proc. Natl.  Acad  Sd. 
U. S. A. 73:1288. 
18.  Winchester, R. J., and H. G. Kunkel. 1979. The human Ia system. Adv. IrnmunoL 28:221. 
19.  Fu, S. M., N. Chiovazzi, C. Y. Wang, G. Montazeri, H. G. Kunkel, H. S. Ko, and A. B. 
Gottlieb.  1978. Ia-bearing T  lymphocytes in  man.  Their  identification and  role in  the 
generation of allogeneic helper activity.J. Exp.  Med. 148:1423. 
20.  Halper, J.,  S. M.  Fu, C.  Y.  Wang, R. Winchester, and H. G. Kunkel.  1978. Patterns of 
expression of human "Ia-like" antigens during the terminal stages of B cell development. 
J. [mmunol. 120:1480. 
21.  Aisenberg, A. C., B. M. Wilkes, J. C. Long, and N. L. Harris. 1980. Cell surface phenotype 
in lymphoproliferative disease. Am. J. Med. 68:206. 
22.  Mann, R. B., E. S. Jaffe, and C. W. Berard.  1979. Malignant lymphomas--a conceptual 
understanding of morphologic diversity. Am. J. Pathol. 94:104. 